Article
Biochemistry & Molecular Biology
Eric Santoni-Rugiu, Maya Jeje Schuang Lu, Jan Nyrop Jakobsen, Linea Cecilie Melchior, Jesper Ravn, Jens Benn Sorensen
Summary: The study found that MET overexpression occurs in a substantial fraction of predominantly epithelioid malignant mesotheliomas, but is poorly correlated with MET amplification status and may impact the likelihood of response to standard chemotherapy for mesothelioma. The predictive significance of MET-IHC and -FISH for possible MET-targeted therapy of mesothelioma remains to be elucidated.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Ibiayi Dagogo-Jack, Lesli A. Kiedrowski, Jochen K. Lennerz
Summary: MET-amplified, ALK + NSCLC often presents with high-level and heterogeneous amplification in tissue, seldom overlaps with ALK mutations, and frequently co-occurs with alterations associated with aggressive tumor biology.
Article
Oncology
Boning Cai, Xiaomo Li, Xiang Huang, Tonghui Ma, Baolin Qu, Wei Yu, Wei Yang, Pei Zhang, Jing Chen, Fang Liu
Summary: EGFR tyrosine kinase inhibitors are standard treatment for NSCLC patients, but resistance is common. Combination of EGFR and MET inhibitors has shown promise, but acquired resistance to MET inhibitors is a challenge. Sequential MET inhibitor use may be effective for EGFR-mutant, MET-amplified NSCLC.
FRONTIERS IN ONCOLOGY
(2021)
Article
Biology
H. S. Abboud, D. Camuzi, D. C. Rapozo, P. Fernandes, P. Nicolau-Neto, S. Guaraldi, T. A. Simao, L. F. Ribeiro Pinto, I. M. Gonzaga, S. C. Soares-Lima
Summary: Esophageal squamous cell carcinoma (ESCC) is a common and deadly cancer with limited effective therapies. The study found that while HGF and MET genetic alterations are not common in ESCC, MET expression is consistently upregulated in tumors, suggesting it as a potential therapeutic target. However, intratumor heterogeneity should be considered for eligibility for HGF-MET targeted therapy.
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
(2021)
Review
Oncology
N. Coleman, L. Hong, J. Zhang, J. Heymach, D. Hong, X. Le
Summary: This article discusses MET amplification as a driver of acquired resistance in NSCLC, exploring the biology behind this mechanism and summarizing clinical data including proposed combination strategies for overcoming acquired MET amplification-dependent resistance.
Article
Oncology
Francesca Bersani, Francesca Picca, Deborah Morena, Luisella Righi, Francesca Napoli, Mariangela Russo, Daniele Oddo, Giuseppe Rospo, Carola Negrino, Barbara Castella, Marco Volante, Angela Listi, Vanessa Zambelli, Federica Benso, Fabrizio Tabbo, Paolo Bironzo, Emanuele Monteleone, Valeria Poli, Filippo Pietrantonio, Federica Di Nicolantonio, Alberto Bardelli, Carola Ponzetto, Silvia Novello, Giorgio V. Scagliotti, Riccardo Taulli
Summary: This study demonstrates that the measurement of circMET levels in the plasma can be used to identify and track patients with high MET activity. It provides a simple, cost-effective, non-invasive approach for implementing patient stratification based on MET expression and monitoring therapy response and clonal evolution during treatment.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2023)
Review
Oncology
Nehad M. Ayoub, Dalia R. Ibrahim, Amer E. Alkhalifa
Summary: Targeted therapy has revolutionized cancer management, but the development of cancer resistance, particularly through MET activation, poses a major obstacle to its effectiveness. Studies on MET inhibitors for overcoming resistance in solid tumors highlight the need for further research and clinical applications.
Article
Oncology
Cristina Chiriaco, Chiara Donini, Marco Cortese, Stefano Ughetto, Chiara Modica, Ilaria Martinelli, Alessia Proment, Letizia Vitali, Lara Fontani, Monica Casucci, Paolo Maria Comoglio, Silvia Giordano, Dario Sangiolo, Valeria Leuci, Elisa Vigna
Summary: The study proposes an immunotherapy strategy using CAR-T lymphocytes targeting MET overexpressing tumors across different histotypes, showing specific cytotoxic activity and potential to overcome acquired resistance to MET targeting agents in cancer cells. The approach holds promise for cancers not responsive to traditional MET inhibition therapies.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2022)
Review
Oncology
Jan Trost Jorgensen, Jens Mollerup
Summary: MET is a receptor tyrosine kinase that plays a significant role in cancer cell progression and is targeted by several drugs under development for the treatment of different cancers. However, the lack of effective biomarkers to select the right patients for treatment may be one of the reasons why relatively few of these drugs have shown sufficient clinical activity and obtained regulatory approval. MET exon 14 skipping mutation and MET amplification detected by FISH are two potential biomarkers, with the former showing sufficient predictive properties and the latter showing promising results in the treatment of NSCLC patients.
Article
Oncology
Yu-Ra Choi, Eun Hye Kang, Sunshin Kim, Seog-Yun Park, Ji-Youn Han, Youngjoo Lee
Summary: This study evaluated the efficacy of single MET inhibition in EGFR-mutant and MET-amplified lung cancer and found that it produced a short-lived response. Further research on novel combination therapy schedules is needed to achieve long-lasting efficacy with less toxicity.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Won Gun Kwack, Ji-Youn Sung, Seung Hyeun Lee
Summary: High Romo1 expression is associated with poor response to EGFR-TKIs treatment and shorter survival in lung adenocarcinoma patients. It indicates the need for active surveillance and tailored therapeutic approach for this subgroup. Additionally, Romo1 may serve as a potential predictive and prognostic biomarker for this patient population.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Kexun Zhou, Yingping Liu, Hong Zhu
Summary: Our study confirms the therapeutic value of a c-MET inhibitor in the treatment of advanced CCA harboring MET amplification and provides an alternative strategy for patients who are intolerant to chemotherapy.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Ezra Y. Rosen, Melissa L. Johnson, Sarah E. Clifford, Romel Somwar, Jennifer F. Kherani, Jieun Son, Arrien A. Bertram, Monika A. Davare, Eric Gladstone, Elena Ivanova, Dahlia N. Henry, Elaine M. Kelley, Mika Lin, Marina S. D. Milan, Binoj C. Nair, Elizabeth A. Olek, Jenna E. Scanlon, Morana Vojnic, Kevin Ebata, Jaclyn F. Hechtman, Bob T. Li, Lynette M. Sholl, Barry S. Taylor, Marc Ladanyi, Pasi A. Janne, S. Michael Rothenberg, Alexander Drilon, Geoffrey R. Oxnard
Summary: The RET proto-oncogene is activated by gene fusion in 1%-2% of NSCLC, while MET amplification is associated with resistance to selpercatinib. Combination therapy with selpercatinib and crizotinib can overcome MET-mediated resistance to RET inhibition.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Shinichiro Suzuki, Kimio Yonesaka, Takeshi Teramura, Toshiyuki Takehara, Ryoji Kato, Hitomi Sakai, Koji Haratani, Junko Tanizaki, Hisato Kawakami, Hidetoshi Hayashi, Kazuko Sakai, Kazuto Nishio, Kazuhiko Nakagawa
Summary: The study identified MET amplification as a mechanism of resistance to KRAS(G12C) inhibitors in NSCLC. Using MET inhibitor Crizotinib restored sensitivity to sotorasib, and dual inhibition of MET and KRAS(G12C) led to tumor shrinkage in sotorasib-resistant xenograft mice.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Thomas Decaens, Carlo Barone, Eric Assenat, Martin Wermke, Angelica Fasolo, Philippe Merle, Jean-Frederic Blanc, Veronique Grando, Angelo Iacobellis, Erica Villa, Joerg Trojan, Josef Straub, Rolf Bruns, Karin Berghoff, Juergen Scheele, Eric Raymond, Sandrine Faivre
Summary: Tepotinib showed good tolerability and promising efficacy at the recommended dose of 500 mg in sorafenib-pretreated aHCC patients with MET overexpression.
BRITISH JOURNAL OF CANCER
(2021)
